Author

Laura Zarzuela

Consejo Superior de Investigaciones Científicas

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Approach:mechanistic / dynamical model· 1

Frequent Co-Authors

Ana Reina-Bando· 1 shared Elena Sánchez-Escabias· 1 shared G. Vignir HelgasoniD· 1 shared Gema Moreno‐BuenoiD· 1 shared Ignacio G. López-Cepero· 1 shared Jesús María Sierra-PárragaiD· 1 shared José C. ReyesiD· 1 shared Kevin M. RattiganiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Ana Reina-Bando

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

FGFR1 inhibition prevents metabolic adaptation associated with therapy resistance in glioblastoma

Laura Zarzuela, Ignacio G. López-Cepero, Kevin M. Rattigan, Elena Sánchez-Escabias, Macarena Morillo‐Huesca, Ana Reina-Bando, Sara S. Oltra, Jesús María Sierra-Párraga, María Ceballos-Chávez, Vivian Capilla‐González, Gema Moreno‐Bueno, Piedad del Socorro Murdoch, José C. Reyes, G. Vignir Helgason, Mercedes Tomé, Raúl V. Durán

This study identifies FGFR1 as a key driver of TMZ resistance in GBM through metabolic rewiring and cell cycle regulation, showing that FGFR1 inhibition restores TMZ sensitivity in preclinical models.

bioRxiv · Jan 11, 2025 · PreprintCancer Biology